Published January 1, 2016
| Version v1
Journal article
Open
IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation
Creators
- Oktay, Yavuz
- Ulgen, Ege1
- Can, Ozge
- Akyerli, Cemaliye B.
- Yuksel, Sirin
- Erdemgil, Yigit1
- Durasi, I. Melis2
- Henegariu, Octavian Ioan3
- Nanni, E. Paolo4
- Selevsek, Nathalie4
- Grossmann, Jonas4
- Erson-Omay, E. Zeynep3
- Bai, Hanwen3
- Gupta, Manu5
- Lee, William6
- Turcan, Sevin7
- Ozpinar, Aysel
- Huse, Jason T.8
- Sav, M. Aydin
- Flanagan, Adrienne5
- Flanagan, Adrienne5
- 1. Acibadem Univ, Brain Tumor Res Grp, Istanbul, Turkey
- 2. Sabanci Univ, Fac Engn & Nat Sci, Dept Biol Sci & Bioengn, Istanbul, Turkey
- 3. Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06504 USA
- 4. UZH ETH, Funct Genom Ctr Zurich, Zurich, Switzerland
- 5. UCL, Canc Inst, 72 Huntley St, London WC1E 6DD, England
- 6. Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA
- 7. Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA
- 8. Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
Description
The single nucleotide polymorphism rs55705857, located in a non-coding but evolutionarily conserved region at 8q24.21, is strongly associated with IDH-mutant glioma development and was suggested to be a causal variant. However, the molecular mechanism underlying this association has remained unknown. With a case control study in 285 gliomas, 316 healthy controls, 380 systemic cancers, 31 other CNS-tumors, and 120 IDH-mutant cartilaginous tumors, we identified that the association was specific to IDH-mutant gliomas. Odds-ratios were 9.25 (5.17-16.52; 95% CI) for IDH-mutated gliomas and 12.85 (5.94-27.83; 95% CI) for IDH-mutated, 1p/19q co-deleted gliomas. Decreasing strength with increasing anaplasia implied a modulatory effect. No somatic mutations were noted at this locus in 114 blood-tumor pairs, nor was there a copy number difference between risk-allele and only-ancestral allele carriers. CCDC26 RNA-expression was rare and not different between the two groups. There were only minor subtype-specific differences in common glioma driver genes. RNA sequencing and LC-MS/MS comparisons pointed to significantly altered MYC-signaling. Baseline enhancer activity of the conserved region specifically on the MYC promoter and its further positive modulation by the SNP risk-allele was shown in vitro. Our findings implicate MYC deregulation as the underlying cause of the observed association.
Files
bib-42931afa-7610-4e2e-8d45-55edd1af5eac.txt
Files
(376 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:5891e5b92c9294b8eff16ced5ddc52f7
|
376 Bytes | Preview Download |